These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24760272)

  • 41. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer.
    Zedan AH; Osther PJS; Assenholt J; Madsen JS; Hansen TF
    Sci Rep; 2020 Jan; 10(1):227. PubMed ID: 31937854
    [TBL] [Abstract][Full Text] [Related]  

  • 43. miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.
    Li X; Jiao M; Hu J; Qi M; Zhang J; Zhao M; Liu H; Xiong X; Dong X; Han B
    Prostate; 2020 Jun; 80(9):674-686. PubMed ID: 32294305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
    Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
    Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MicroRNA-19a regulates proliferation and apoptosis of castration-resistant prostate cancer cells by targeting BTG1.
    Lu K; Liu C; Tao T; Zhang X; Zhang L; Sun C; Wang Y; Chen S; Xu B; Chen M
    FEBS Lett; 2015 Jun; 589(13):1485-90. PubMed ID: 25936765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.
    Lin HM; Mahon KL; Spielman C; Gurney H; Mallesara G; Stockler MR; Bastick P; Briscoe K; Marx G; Swarbrick A; Horvath LG
    Br J Cancer; 2017 Apr; 116(8):1002-1011. PubMed ID: 28278515
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6).
    Liu D; Tao T; Xu B; Chen S; Liu C; Zhang L; Lu K; Huang Y; Jiang L; Zhang X; Huang X; Zhang L; Han C; Chen M
    Biochem Biophys Res Commun; 2014 Feb; 445(1):151-6. PubMed ID: 24491557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
    Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
    Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual strands of pre-miR‑150 (miR‑150‑5p and miR‑150‑3p) act as antitumor miRNAs targeting SPOCK1 in naïve and castration-resistant prostate cancer.
    Okato A; Arai T; Kojima S; Koshizuka K; Osako Y; Idichi T; Kurozumi A; Goto Y; Kato M; Naya Y; Ichikawa T; Seki N
    Int J Oncol; 2017 Jul; 51(1):245-256. PubMed ID: 28534948
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
    Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
    Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MicroRNA-1205, encoded on chromosome 8q24, targets EGLN3 to induce cell growth and contributes to risk of castration-resistant prostate cancer.
    Wang Y; Li X; Liu W; Li B; Chen D; Hu F; Wang L; Liu XM; Cui R; Liu R
    Oncogene; 2019 Jun; 38(24):4820-4834. PubMed ID: 30808975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer.
    Sun T; Yang M; Chen S; Balk S; Pomerantz M; Hsieh CL; Brown M; Lee GM; Kantoff PW
    Prostate; 2012 Jul; 72(10):1093-103. PubMed ID: 22127852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MicroRNA in prostate cancer: Practical aspects.
    Patil PA; Magi-Galluzzi C
    Histol Histopathol; 2015 Dec; 30(12):1379-96. PubMed ID: 26186079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
    Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
    Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome.
    Strand SH; Schmidt L; Weiss S; Borre M; Kristensen H; Rasmussen AKI; Daugaard TF; Kristensen G; Stroomberg HV; Røder MA; Brasso K; Mouritzen P; Sørensen KD
    Sci Rep; 2020 Jul; 10(1):10704. PubMed ID: 32612164
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression.
    Sugie S; Mukai S; Yamasaki K; Kamibeppu T; Tsukino H; Kamoto T
    Hum Cell; 2016 Jan; 29(1):22-9. PubMed ID: 26250899
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
    Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
    Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MicroRNA-4719 and microRNA-6756-5p Correlate with Castration-Resistant Prostate Cancer Progression through Interleukin-24 Regulation.
    Das DK; Persaud L; Sauane M
    Noncoding RNA; 2019 Jan; 5(1):. PubMed ID: 30669553
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer.
    Xu B; Wang N; Wang X; Tong N; Shao N; Tao J; Li P; Niu X; Feng N; Zhang L; Hua L; Wang Z; Chen M
    Prostate; 2012 Aug; 72(11):1171-8. PubMed ID: 22161865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.